Catalytic (Labile) Iron in Kidney Disease

Seldin and Giebisch's The Kidney: Physiology and Pathophysiology

Volumn , Issue , 2012, Pages 3007-3020

  Rajapurkar, Mohan ^a   Baliga, Radhakrishna ^b   Shah, Sudhir V ^c  

^a MULJIBHAI PATEL UROLOGICAL HOSPITAL   (India)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84924096357     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-381462-3.00089-6     Document Type: Chapter

References (92)

1. Chertow G.M., Burdick E., Honour M., Bonventre J.V., Bates D.W. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 2005, 16(11):3365-3370.
2. Mehta R.L., Kellum J.A., Shah S.V., Molitoris B.A., Ronco C., Warnock D.G., et al. Acute kidney injury network (AKIN): report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007, 11(2):R31.
3. Lafrance J.-P., Miller D.R. Acute kidney injury associates with inreased long-term mortality. J Am Soc Nephrol 2010, 21:345-352.
4. Hobson C.E., Yavas S., Segal M.S., Schold J.D., Tribble C.G., Layon A.J., et al. Acute kidney injury is associated with increased long-term mortality after cardiothoracic surgery. Circulation 2009, 119:2444-2453.
5. Hsu C. Linking the population epidemiology of acute renal failure, chronic kidney disease and end-stage renal disease. Curr Opin Nephrol Hypertens 2007, 16:221-226.
6. Triverio P.-A., Martin P.-Y., Romand J., Pugin J., Perneger T., Saudan P. Long-term prognosis after acute kidney injury requiring renal replacement therapy. Nephrol Dial Transplant 2009, 24(7):2186-2189.
7. Coresh J., Selvin E., Stevens L.A., Manzi J., Kusek J.W., Eggers P., et al. Prevalence of chronic kidney disease in the United States. JAMA 2007, 298(17):2038-2047.
8. Xue J.L., Ma J.Z., Louis T.A., Collins A.J. Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol 2001, 12:2753-2758.
9. Sarnak M.J., Levey A.S., Schoolwerth A.C., Coresh J., Culleton B.F., Hamm L.L., et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American heart association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation 2003, 108(17):2154-2169.
10. Szczech L.A., Lazar I.L. Projecting the United States ESRD population: Issues regarding treatment of patients with ESRD. Kidney Int 2004, 66(Suppl. 90):S3-S7.
11. Lambers Heerspink H., Greene T., Lewis J.B., Raz I., Rohde R.D., Hunsicker L.G., et al. Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria. Nephrol Dial Transplant 2007, 23(6):1946-1954.
12. Zager R.A. Combined mannitol and deferoxamine therapy for myohemoglobinuric renal injury and oxidant tubular stress. Mechanistic and therapeutic implications. J Clin Invest 1992, 90:711-719.
13. Rajapurkar M., Gang S., Hegde U., Gohel K., Shah S.V. Study of urinary catalytic (bleomycin-detectable) iron following radiocontrast exposure in healthy kidney donors [abstract]. J Am Soc Nephrol 2007, 18:575A.
14. Kruszewski M. The role of labile iron pool in cardiovascular diseases. Acta Biochim Pol 2004, 51(2):471-480.
15. Halliwell B., Gutteridge J.M. Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol 1990, 186:1-85.
16. Kakhlon O., Cabantchik Z.I. The labile iron pool: characterization, measurement, and participation in celullar processes. Free Rad Biol Med 2002, 33(8):1037-1046.
17. Andrews N.C. Forging a field: the golden age of iron biology. Blood 2008, 112(2):219-230.
18. Ganz T., Nemeth E. Hepcidin and disorders of iron metabolism. Annu Rev Med 2011, 62:347-360.
19. Esposito B.P., Breuer W., Slotki I., Cabantchik Z.I. Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients. Euro J Clin Invest 2002, 32(Suppl. 1):42-49.
20. Lai C.C., Huang W.H., Klevay L.M., Gunning W.T., Chiu T.H. Antioxidant enzyme gene transcription in copper-deficient rat liver. Free Radic Biol Med 1996, 21:233-240.
21. Gutteridge J.M.C., Rowley D.A., Halliwell B. Superoxide-dependent formation of hydroxyl radicals in the presence of iron salts. Detection of 'free' iron in biological systems by using bleomycin-dependent degradation of DNA. Biochem J 1981, 199:263-265.
22. Gutteridge J.M.C., Cao W., Chevion M. Bleomycin-detectable iron in brain tissue. Free Rad Res Comm 1991, 11(6):317-320.
23. Esposito B.P., Breuer W., Sirankapracha P., Pootrakul P., Hershko C., Cabantchik I. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood 2003, 102(7):2670-2677.
24. Sohn Y.S., Breuer W., Munnich A., Cabantchik Z.I. Redistribution of accumulated cell iron: a modality of chelation with therapeutic implications. Blood 2008, 111(3):1690-1699.
25. Boddaert N., Le Quan Sang K.H., Rötig A., Leroy-Willig A., Gallet S., Brunelle F., et al. Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood 2007, 110(1):401-408.
26. Bywaters E.G.L., Beall D. Crush injuries with impairment of renal function. Br Med J 1941, 1:427-432.
27. Gabow P.A., Kaehny W.D., Kelleher S.P. The spectrum of rhabdomyolysis. Medicine 1982, 61(3):141-152.
28. Hostetter T.H., Wilkes B.M., Brenner B.M. Renal circulatory and nephron function in experimental acute renal failure. Acute renal failure 1983, Vol 1:99-115. W.B. Saunders Company, Philadelphia. 1st ed.
29. Baliga R., Zhang Z., Baliga M., Shah S.V. Evidence for cytochrome P-450 as a source of catalytic iron in myoglobinuric acute renal failure. Kidney Int 1996, 49:362-369.
30. Shah S.V. Evidence suggesting a role for hydroxyl radical in passive Heymann nephritis in rats. Am J Physiol 1988, 254(23):F337-F344.
31. Paller M.S. Hemoglobin- and myoglobin-induced acute renal failure in rats: role of iron in nephrotoxicity. Am J Physiol 1988, 255(24):F539-F544.
32. Paller M.S., Jacob H.S. Cytochrome P-450 mediates tissue-damaging hydroxyl radical formation during reoxygenation of the kidney. Proc Natl Acad Sci USA 1994, 91:7002-7006.
33. Baliga R., Zhang Z., Baliga M., Ueda N., Shah S.V. In vitro and in vivo evidence suggesting a role for iron in cisplatin-induced nephrotoxicity. Kidney Int 1998, 53:394-401.
34. Baliga R., Zhang Z., Baliga M., Ueda N., Shah S.V. Role of cytochrome P-450 as a source of catalytic iron in cisplatin-induced nephrotoxicity. Kidney Int 1998, 54:1562-1569.
35. Liu H., Baliga R. Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int 2003, 63:1687-1696.
36. Ueda N., Guidet B., Shah S.V. Gentamicin-induced mobilization of iron from renal cortical mitochondria. Am J Physiol 1993, 265(34):F435-F439.
37. Walker P.D., Shah S.V. Evidence suggesting a role for hydroxyl radical in gentamicin-induced acute renal failure in rats. J Clin Invest 1988, 81:334-341.
38. Yang C.L., Du X.H., Han Y.X. Renal cortical mitochondria are the source of oxygen free radicals enhanced by gentamicin. Renal Failure 1995, 17(1):21-26.
39. Kays S.E., Crowell W.A., Johnson M.A. Iron supplementation increases gentamicin nephrotoxicity in rats. J Nutr 1991, 121:1869-1875.
40. Ben Ismail T.H., Ali B.H., Bashir A.A. Influence of iron, deferoxamine and ascorbic acid on gentamicin-induced nephrotoxicity in rats. Gen Pharmacol 1994, 25(6):1249-1252.
41. Parvez Z., Rahman M.A., Moncada R. Contrast media-induced lipid peroxidation in the rat kidney. Invest Radiol 1989, 24:697-702.
42. Bakris G.L., Lass N., Gaber A.O., Jones J.D., Burnett J.C. Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals. Am J Physiol 1990, 258:F115-F120. [Renal Fluid Electrolyte Physiol 27].
43. Yoshioka T., Fogo A., Beckman J.K. Reduced activity of antioxidant enzymes underlies contrast media-induced renal injury in volume depletion. Kidney Int 1992, 41:1008-1015.
44. Efrati S., Dishy V., Averbukh M., Blatt A., Krakover R., Weisgarten J., et al. The effect of N-acetylcysteine on renal function, nitric oxide, and oxidative stress after angiography. Kidney Int 2003, 64(6):2182-2187.
45. Drager L.F., Andrade L., Barros De Toledo J.F., Laurindo F.R., Machado Cesar L.A., Seguro A.C. Renal effects of N-acetylcysteine in patients at risk for contrast nephropathy: decrease in oxidant stress-mediated renal tubular injury. Nephrol Dial Transplant 2004, 19(7):1803-1807.
46. Sandler C.M. Contrast-agent-induced acute renal dysfunction--is iodixanol the answer?. N Engl J Med 2003, 348(6):551-553.
47. Vari R.C., Natarajan L.A., Whitescarver S.A., Jackson B.A., Ott C.E. Induction, prevention and mechanisms of contrast media-induced acute renal failure. Kidney Int 1988, 33(3):699-707.
48. Hanss B.G., Valencia S.H., Shah S.V., Vari R.C. The iron chelator deferoxamine prevents contrast media induced acute renal failure in the rabbit [abstract]. J Am Soc Nephrol 1990, 1(4):612.
49. Baliga R., Ueda N., Shah S.V. Increase in bleomycin-detectable iron in ischaemia/reperfusion injury to rat kidneys. Biochem J 1993, 291(3):901-905.
50. Paller M.S., Hedlund B.E. Role of iron in postischemic renal injury in the rat. Kidney Int 1988, 34:474-480.
51. Huang H., He Z., Roberts L.J., Salahudeen A.K. Deferoxamine reduces cold-ischemic renal injury in a syngeneic kidney transplant model. Am J Transplant 2003, 3:1531-1537.
52. de Vries B., Walter S.J., von BonsdorffL., Wolfs T.G., van Heurn L.W., Parkkinen J., et al. Reduction of circulating redox-active iron by apotransferrin protects against renal ischemia-reperfusion injury. Transplantation 2004, 77(5):669-675.
53. Yang T., Brittenham G.M., Dong W.-Q., Levy M.N., Obejero-Paz C.A., Kuryshev Y.A., et al. Deferoxamine prevents cardiac hypertrophy and failure in the gerbil model of iron-induced cardiomyopathy. J Lab Clin Med 2003, 142(5):332-340.
54. Mishra J., Mori K., Ma Q., Kelly C., Yang J., Mitsnefes M., et al. Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol 2004, 15:3073-3082.
55. Devarajan P. Update on mechanisms of ischemic acute kidney injury. J Am Soc Nephrol 2006, 17(6):1503.
56. Voogd A., Sluiter W., van Eijk H.G., Koster J.F. Low molecular weight iron and the oxygen paradox in isolated rat hearts. J Clin Invest 1992, 90:2050-2055.
57. Nath K.A., Norby S.M. Reactive oxygen species and acute renal failure. Am J Med 2000, 109:555-578.
58. Kruszewski M. Labile iron pool: the main determinant of cellular response to oxidative stress. Mutat Res 2003, 531:81-92.
59. van der Kraaij A.M.M., Mostert L.J., van Eijk H.G., Koster J.F. Iron-load increases the susceptibility of rat hearts to oxygen reperfusion damage. Protection by the antioxidant (+)-cyanidanol-3 and deferoxamine. Circulation 1988, 78:442-449.
60. van der Kraaij A.M.M., van Eijk H.G., Koster J.F. Prevention of postischemic cardiac injury by the orally active iron chelator 1,2-dimethyl-3-hydroxy-4-pyridone (L1) and the antioxidant (+)-cyanidanol-3. Circulation 1989, 80:158-164.
61. Nicholson S.C., Squier M., Ferguson D.J.P., Nagy Z., Westaby S., Evans R.D. Effect of desferrioxamine cardioplegia on ischemia-reperfusion in isolated rat heart. Ann Thorac Surg 1997, 63:1003-1011.
62. Paraskevaidis J.A., Iliodromitis E.K., Vlahakos D., Tsiapras D.P., Nikolaidis A., Marathias A., et al. Deferoxamine infusion during coronary artery bypass grafting ameliorates lipid peroxidation and protects the myocardium against reperfusion injury: immediate and long-term significance. Euro Heart J 2005, 26(3):263-270.
63. Boyce N.W., Holdsworth S.R. Hydroxyl radical mediation of immune renal injury by desferrioxamine. Kidney Int 1986, 30:813-817.
64. Ueda N., Baliga R., Shah S.V. Role of "catalytic" iron in an animal model of minimal change nephrotic syndrome. Kidney Int 1996, 49:370-373.
65. Thakur V., Walker P.D., Shah S.V. Evidence suggesting a role for hydroxyl radical in puromycin aminonucleoside-induced proteinuria. Kidney Int 1988, 34:494-499.
66. Liu H., Shah S.V., Baliga R. Cytochrome P-450 as a source of catalytic iron in minimal change nephrotic syndrome in rats. Am J Physiol Renal Physiol 2001, 280:F88-F94.
67. Liu H., Bigler S.A., Henegar J.R., Baliga R. Cytochrome P450 2B1 mediates oxidant injury in puromycin-induced nephrotic syndrome. Kidney Int 2002, 62(3):868-876.
68. Tian N., Arany I., Waxman D.J., Baliga R. Cytochrome P450 2B1 gene silencing attenuates puromycin aminonucleoside-induced cytotoxicity to glomerular epithelial cells. Kidney Int 2010, 78(2):182-190.
69. Baliga R., Ueda N., Shah S.V. Kidney iron status in passive Heymann nephritis and the effect of iron deficient diet. J Am Soc Nephrol 1996, 7:1183-1188.
70. Harris D.C., Tay C., Nankivell B.J. Lysosomal iron accumulation and tubular damage in rat puromycin nephrosis and ageing. Clin Exp Pharmacol Physiol 1994, 21(2):73-81.
71. Alfrey A.C. Toxicity of tubule fluid iron in the nephrotic syndrome. Am J Physiol 1992, 263(32):F637-F641.
72. Cooper M.A., Buddington B., Miller N.L., Alfrey A.C. Urinary iron speciation in nephrotic syndrome. Am J Kidney Dis 1995, 25(2):314-319.
73. Nankivell B.J., Chen J., Boadle R.A., Harris D.C.H. The role of tubular iron accumulation in the remnant kidney. J Am Soc Nephrol 1994, 4:1598-1607.
74. Remuzzi A., Puntorieri S., Brugnetti B., Bertani T., Remuzzi G. Renoprotective effect of low iron diet and its consequence on glomerular hemodynamics. Kidney Int 1991, 39:647-652.
75. Alfrey A.C., Froment D.H., Hammond W.S. Role of iron in the tubulo-interstitial injury in nephrotoxic serum nephritis. Kidney Int 1989, 36:753-759.
76. Howard R.L., Buddington B., Alfrey A.C. Urinary albumin, transferrin and iron excretion in diabetic patients. Kidney Int 1991, 40:923-926.
77. Rajapurkar M.M., Alam M.G., Bhattacharya A. Novel treatment for diabetic nephropathy [abstract]. J Am Soc Nephrol 2007, 18:329A.
78. Nankivell B.J., Boadle R.A., Harris D.C.H. Iron accumulation in human chronic renal disease. Am J Kidney Dis 1992, 20(6):580-584.
79. Rajapurkar M.M., Baliga R., Shah S.V. Treatment of patients with glomerulonephritis with an oral iron chelator [abstract]. J Am Soc Nephrol 2007, 18:57-58A.
80. Lin J.-L., Lin-Tan D.-T., Hsu K.-H., Yu C.-C. Environmental lead exposure and progression of chronic renal diseases in patients without diabetes. N Engl J Med 2003, 348(4):277-286.
81. Owda A.K., Alam M.G., Shah S.V. Environmental lead exposure and chronic renal disease. N Engl J Med 2003, 348(18):1810.
82. Nakamoto M., Shapiro J.I., Shanley P.F., Chan L., Schrier R.W. In vitro and in vivo protective effect of atriopeptin III on ischemic acute renal failure. J Clin Invest 1987, 80(3):698-705.
83. Allgren R.L., Marbury T.C., Rahman S.N., Weisberg L.S., Fenves A.Z., Lafayette R.A., et al. Anaritide in acute tubular necrosis. N Eng J Med 1997, 336(12):828-834.
84. Ding H., Kopple J.D., Cohen A., Hirschberg R. Recombinant human insulin-like growth factor-I accelerates recovery and reduces catabolism in rats with ischemic acute renal failure. J Clin Invest 1993, 91:2281-2287.
85. Hirschberg R., Kopple J., Lipsett P., Benjamin E., Minei J., Albertson T., et al. Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure. Kidney Int 1999, 55:2423-2432.
86. Siegel N.J., Gaudio K.M., Katz L.A., Reilly H.F., Ardito T.A., Hendler F.G., et al. Beneficial effect of thyroxin on recovery from toxic acute renal failure. Kidney Int 1984, 25:906-911.
87. Acker C.G., Singh A.R., Flick R.P., Bernadini J., Greenberg A., Johnson J.P. A trial of thyroxine in acute renal failure. Kidney Int 2000, 57:293-298.
88. Heyman S.N., Brezis M., Greenfeld Z., Rosen S. Protective role of furosemide and saline in radiocontrast-induced acute renal failure in the rat. Am J Kidney Dis 1989, 14(5):377-385.
89. Solomon R., Werner C., Mann D., D'Elia J., Silva P. Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994, 331(21):1416-1420.
90. de Brito-Ashurst I., Varagunam M., Raftery M.J., Yaqoob M.M. Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol 2009, 20:2075-2084.
91. Cho M.E., Smith D.C., Branton M.H., Penzak S.R., Kopp J.B. Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2007, 2:906-913.
92. Cohen A.R. New advances in iron chelation therapy. Hematology Am Soc Hematol Educ Program 2006, 42-47.